Cytori Therapeutics (CYTX) Reports APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Funct
Tweet
Share
E-mailGet Alerts CYTX Hot Sheet
Join SI Premium – FREE
Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of previously reported six-month outcomes from APOLLO, the Company's European clinical trial evaluating adipose-derived stem and regenerative cells in patients with acute myocardial infarction, as Research Correspondence in the Journal of the American College of Cardiology.
The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA) evaluating autologous ADRCs extracted with the Company's proprietary Celution(R) System for the treatment of patients suffering from acute myocardial infarction.
The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA) evaluating autologous ADRCs extracted with the Company's proprietary Celution(R) System for the treatment of patients suffering from acute myocardial infarction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Takeda's rusfertide for polycythemia vera treatment
- FDA approves Moderna's updated 2026-2027 COVID-19 vaccines
- Quoin Pharmaceuticals reports interim Phase 2/3 data for QRX003
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
